Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method of nociceptor differentiation of human embryonic stem cells and uses thereof

a technology of human embryonic stem cells and nociceptors, applied in the field of stem cell biology, can solve the problems of reducing the activity of signal molecule activity, reducing the level of smad protein, and preventing downstream smad activation.

Inactive Publication Date: 2016-07-14
MEMORIAL SLOAN KETTERING CANCER CENT
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0091]As used herein, the term “passage” in reference to a cell culture, refers to the process in which cells are disassociated, washed, and seeded into new culture vessels after a round of cell growth and proliferation. The number of passages a line of cultured cells has gone through is an indication of its age and expected stability.

Problems solved by technology

There is a current lack of knowledge relating to the directed differentiation of embryonic and somatic stem cells toward lineages of the peripheral nervous system (PNS).
Diseases of peripheral sensory neurons of the PNS are of particular societal burden because they result in severe pain or failure to respond to noxious stimuli causing injury and include diseases such as Familial Dysautonomia, congenital insensitivity to pain, diabetic neuropathies, and damage due to infections of Varicella or herpes zoster.
Understanding the pathology of peripheral sensory neuron diseases, as well as development of treatment modalities, is hindered by the difficulties in obtaining human peripheral sensory neurons; current methods are limited to manual isolation from 3-5 week old human embryos or rare surgical procedures.
However, these techniques are limited by the need for a neuronal intermediate, co-culture with murine stromal cells, length of time to derive such peripheral sensory neurons, low yield, impure populations of cells containing mixed neuronal types, limited survival and poor characterization of PNS generated neurons.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of nociceptor differentiation of human embryonic stem cells and uses thereof
  • Method of nociceptor differentiation of human embryonic stem cells and uses thereof
  • Method of nociceptor differentiation of human embryonic stem cells and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example i

Materials and Methods

[0266]The following examples describe exemplary materials and methods used during the development of the present inventions.

[0267]Cells and Culture Conditions.

[0268]Human embryonic stem cell (hESC) cell (WA-09; passages 32-50) and hiPSC lines (C14, C72; passages 10-20) were cultured with mouse embryonic fibroblasts (MEFs, Globalstem, Rockville, State of Maryland, United States of America (USA)) pre-plated at 12-15,000 cells / cm2. Human induced pluripotent stem cell (hiPSC) lines were generated as reported (Papapetrou, et al., Proc Natl Acad Sci USA 106, (2009), herein incorporated by reference). Medium containing Dulbecco's Modified Eagle Medium (DMEM) / F12, 20% knockout serum replacement, 1 mM L-glutamine (Invitrogen, Carlsbad, State of California, USA), 100 μM MEM non-essential amino acids (Invitrogen), and 0.1 mM β-mercaptoethanol (Invitrogen) was made. 6 ng / ml Fibroblast growth factor 2 (FGF-2, R&D Systems, Minneapolis, State of Minnesota) was added after ster...

example ii

Contacting Human Pluripotent Stem Cells with SB431542 and LDN-193189 (LSB) Produced Neural Lineage Cells

[0277]The following example describes exemplary methods for providing cells of a neural lineage for use during development of the present inventions.

[0278]Dual SMAD inhibition was previously used as a rapid and highly effective method for inducing one type of neural lineage cells from hPSCs (Chambers, et al., Nat Biotechnol 27, (2009), herein incorporated by reference). These neural lineage cells induced by molecules including Noggin, had a default pathway that allowed development into central nervous system cells, i.e. neural cell fate. Follow up studies reported the use of a small molecule dorsomorphin (DM) instead of Noggin, that at least in part produced similar cells with differences in consistency of cultures (Kim, et al., Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity. Stem Cell Re...

example iii

Screening Small Molecules Using Neuronal Lineage Cells of the Present Inventions Resulted in Compounds that Produced PAX6 Low and TUJ1 High Neuronal Cells

[0281]The following example describes using exemplary cells of a neural lineage from Example II for screening small molecule candidate compounds for use in directed differentiation.

[0282]Specifically, in the context of dual SMAD inhibition (LSB), i.e. human ES cells were first treated with LSB (LDN-193189 and SB431542) for screening candidate compounds (i.e. small molecules) under approximately 400 conditions in order to find combinations of small molecules that might accelerate the acquisition of postmitotic neuron markers starting from human ES cells. Candidate compounds were chosen from molecules that targeted (altered) cell signaling pathways known to be important and frequently used in developmental studies in order to determine cell fates (for example, signaling pathways such as FGF, Notch, WNT, SHH (Sonic Hedgehog), etc.) fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the field of stem cell biology, in particular the linage specific differentiation of pluripotent or multipotent stem cells, which can include, but is not limited to, human embryonic stem cells (hESC), human induced pluripotent stem cells (hiPSC), somatic stem cells, cancer stem cells, or any other cell capable of lineage specific differentiation. Specifically described are methods to direct the lineage specific differentiation of hESC and / or hiPSC to nociceptors (i.e. nociceptor cells) using novel culture conditions. The nociceptors made using the methods of the present invention are further contemplated for various uses including, but limited to, use in in vitro drug discovery assays, pain research, and as a therapeutic to reverse disease of, or damage to, the peripheral nervous system (PNS). Further, compositions and methods are provided for producing melanocytes from human pluripotent stem cells for use in disease modeling.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation of U.S. application Ser. No. 13 / 697,274 filed Jan. 22, 2013, which is a national phase application filed under 35 U.S.C. §371 as a national stage of International Application Serial No PCT / US2011 / 037179, filed May 19, 2011, which claims priority of U.S. Provisional Application Ser. No. 61 / 396,257, filed May 25, 2010, the contents of each of which are incorporated by reference in their entirety, and to each of which priority is claimed.SEQUENCE LISTING[0002]The specification further incorporates by reference the Sequence Listing submitted herewith via EFS on Mar. 22, 2016. Pursuant to 37 C.F.R. §1.52(e)(5), the Sequence Listing text file, identified as 0727340390SEQ.txt, is 14,403 bytes and was created on Mar. 22, 2016. The Sequence Listing, electronically filed herewith, does not extend beyond the scope of the specification and thus does not contain new matter.FIELD OF THE INVENTION[0003]The present inve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N5/079G01N33/50
CPCC12N5/0618G01N33/5023C12N2501/40C12N2506/02C12N2506/45G01N33/5058C12N5/0626C12N2501/13C12N2501/15C12N2501/155C12N2501/16C12N2501/415C12N2501/727C12N5/062A61P25/02A61P43/00
Inventor STUDER, LORENZCHAMBERS, STUART M.
Owner MEMORIAL SLOAN KETTERING CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com